Details for New Drug Application (NDA): 218312
✉ Email this page to a colleague
The generic ingredient in FONDAPARINUX SODIUM is fondaparinux sodium. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the fondaparinux sodium profile page.
Summary for 218312
| Tradename: | FONDAPARINUX SODIUM |
| Applicant: | Brightgene |
| Ingredient: | fondaparinux sodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 2.5MG/0.5ML (2.5MG/0.5ML) | ||||
| Approval Date: | Dec 18, 2024 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
